Ling Rui Pharmaceutical (600285.SH) announced its first-half results, with net profit of 495 million yuan to mother, an increase of 4.36% over the previous year

According to Zhitong Finance App News, Ling Rui Pharmaceutical (600285.SH) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 2,148 billion yuan, an increase of 2.32% over the previous year. Achieved net profit of 495 million yuan attributable to shareholders of listed companies, an increase of 4.36% over the previous year. Achieved net profit of 465 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 5.06% over the previous year. Basic earnings per share were $0.874.

During the reporting period, the company continued to be deeply involved in the fields of secondary development of existing large varieties, high-end generic drugs, etc., and related R&D work continued to advance. The company is steadily advancing evidence-based medical research and the expansion of indications with standardized and systematic clinical research data to consolidate product efficacy evidence and dig deeper into clinical value; the company's core product, Peiyuan Tongnao capsules, were selected as “TCM Rehabilitation Guidelines for Aphasia after Stroke”; Rui Shuan® fentanyl transdermal patch was selected as “NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain, Version 1.2026” (NCCN) Clinical Practice Guidelines: Adult Cancer Pain (V1.2026 edition); Research results on the indications for post-cold rhinitis of Pilitine® phenylcycloquine ammonium bromide nasal spray were published in relevant international medical journals, effectively enhancing the product's industry influence and clinical recognition, and establishing a strong academic foundation for market expansion. The company is steadily advancing the research and development process of high-end generic drug types, and has been approved for nitrastine hydrochloride nasal spray and aluminum magnesium carbonate chewable tablets; obtained supplementary application approval notices for itchy skin particles to further improve product layout in the fields of respiratory system, gastroenterology and dermatology; continuously optimize the production and preparation process of topical preparations, accelerate the implementation and transformation of innovative achievements, and obtain patent authorizations related to Sanhuang Pearl Cream, further consolidating the company's intellectual property layout in the field of specialty topical formulations.